Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | MPI | P34949 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512092 | 0.87 | MAPT (0.67) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL29435299 | 0.87 | MAPT (0.67) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL527567 | 0.84 | HTT (0.72) | HTTTDP1SMN1; SMN2MAPTHPGD | |
| SCHEMBL29441283 | 0.84 | HTT (0.72) | HTTTDP1SMN1; SMN2MAPTHPGD | |
| SCHEMBL5390051 | 0.83 | HSD17B10 (0.51) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL2837710 | 0.83 | HSD17B10 (0.60) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL10935041 | 0.83 | HTT (0.53) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL30571397 | 0.82 | MAPT (0.62) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL5431670 | 0.82 | MAPT (0.62) | HTTHSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL2910419 | 0.82 | CYP19A1 (0.57) | HTTHSD17B10TDP1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102617358-A | Preparation method of arylamine | LIANYUNGANG JINDUN AGROCHEMICAL CO LTD | 2012-08-01 | — | — | CN | claimed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| CN-116574103-A | Imidazo [1,2-a ] pyridine fused 1, 3-benzodiazepine derivative and synthesis method thereof | 湖北科技学院 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| CN-110483366-B | Indole compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-09-16 | — | — | CN | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-87100191-A | The hydroxy acid derivative of treatment diabetic complication | — | 1987-09-09 | — | — | CN | disclosed |
| EP-0232932-A1 | 5,6-Dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-diones | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-08-19 | — | — | EP | disclosed |
| WO-1987004344-A1 | HYDROXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
| EP-0230379-A2 | Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications | PFIZER INC. (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4287372-A | Preparation of nitro-substituted diphenyl ethers | UOP INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4153800-A | Isoindolinone pigments | CIBA-GEIGY CORPORATION (US) | 1979-05-08 | — | — | US | disclosed |
| US-4126626-A | DYES, POLYESTERS | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-4070367-A | FASTNESS, YELLOW, PLASTICS, LACQUERS, PRINTING INKS | CIBA-GEIGY CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
| US-4008272-A | OXIDATION COLOR DYES, HAIR | SOCIETE ANONYME DITE: L'OREAL (FR) | 1977-02-15 | — | — | US | disclosed |
| US-3948596-A | Oxidation dye for keratinic fibers containing 2-halo-5-acetaminophenol as a coupler | SOCIETE ANONYME DITE: L'OREAL (FR) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HTT 4598/4885HSD17B10 4781/4885TDP1 1115/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | HTT 1359/4885HSD17B10 1464/4885TDP1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.